1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for The Portal Hypertensive Phenotype of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A National Inpatient Sample Analysis, 2020-2023

MPN - 415

The Portal Hypertensive Phenotype of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A National Inpatient Sample Analysis, 2020-2023

Tong Ren

Poster Presenter: Tong Ren

$Thumbnail for Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas$

TCL - 416

Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas

Swaminathan Iyer

Poster Presenter: Swaminathan Iyer

SOHO 2026 Annual Meeting

Topics

The Portal Hypertensive Phenotype of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A National Inpatient Sample Analysis, 2020-2023

Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas

Diagnostic Accuracy of Noncoding RNAs in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Comparative Efficacy of Zanubrutinib in Relapsed/Refractory CLL: Prolonged Progression-Free Survival From a Population-Adjusted Indirect Comparison Using Multilevel Network Meta-Regression

Prognostic Significance of Baseline SUVmax in Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Cost-Effective Analysis of Teclistamab and Daratumumab vs Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma

Assessment of the serum level of soluble CD147 in patients with multiple myeloma

Dual Targeting of FLT3 Signaling and BCL2 Dependency by Venetoclax in ATO-Resistant FLT3-ITD Acute Promyelocytic Leukemia

Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort